TITLE

Grab a bag of stem cells

AUTHOR(S)
Coghlan, Andy
PUB. DATE
February 2016
SOURCE
New Scientist;2/13/2016, Vol. 229 Issue 3060, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the importance of the development of stem cell therapy. Topics mentioned include the use of the stem cell therapy in pharmaceutical industry, the insights of Donna Skerrett, chief medical officer at regenerative medicine company Mesoblast, on the stem cell therapy, and the back pain management. Also mentioned are the blindness treatment and the insights of Michael West of stem cell company BioTime on the development of stem cells products in pharmaceutical firms.
ACCESSION #
112938978

 

Related Articles

  • UNITED KINGDOM PHARMACEUTICALS.  // Acquisdata Industry SnapShots: United Kingdom Pharmaceuticals;10/7/2015, Issue 3532, preceding p1 

    An industry report of the pharmaceuticals industry in Great Britain as of October 2015 is presented from publisher Acquisdata Pty Ltd., with topics including a stem cell trial for a potential cure for blindness, the economic contribution of the industry and leading British pharmaceutical companies.

  • Showcasing Mesoblast: The world leader in regenerative medicine products.  // Australasian Biotechnology;Mar2013, Vol. 23 Issue 1, p16 

    The article features the Australia-based regenerative medicine products supplier Mesoblast. Topics discussed include the company's Mesenchymal Precursor Cell (MPC) technology platform for diabetes treatment, its strategic alliance with Teva Pharmaceutical Industries Ltd. to develop stem cell...

  • SPOTLIGHT. Hill, Joanna // Australasian Biotechnology;Apr2010, Vol. 20 Issue 1, p40 

    The article presents information on Mesoblast Ltd. stocks, an Australian biotechnology stock which is offered at two Australian dollars and 14 cents per share. The company is involved with the development of treatments for orthopaedic conditions including stem cell technology for the...

  • Heart treatment success. Walters, Kath // BRW;5/21/2009, Vol. 31 Issue 20, p12 

    The article reports on the results of a clinical trial on the effectiveness of Revascor, a treatment for heart failure developed by Mesoblast Ltd. It notes that the patients who received a dose of Revascor showed 37% improvement in their heart function. Results also showed that the treatment has...

  • Mesoblast's Stem Cell Therapy Works in Phase II HF Trial. Moran, Nuala // BioWorld Today;11/16/2011, Vol. 22 Issue 223, p1 

    The article reports on the success of Mesoblast Ltd. in reviving the use of stem cells to treat heart disease based on the results of its Phase II heart failure trial of Revascor. Accordingly, a Phase III trial is expected to begin in the U.S. in the first half of 2012. Emerson Perin, director...

  • Stem cells culled from the bone marrow of healthy donors work as well or even better as cells harvested from patients themselves as a treatment for damaged hearts and are more convenient to use, according to new research.  // MondayMorning;11/12/2012, Vol. 20 Issue 43, p1 

    The article reports on a study to examine effectiveness of bone marrow-derived stem cells from healthy donors over stem cells derived from patients themselves for treating heart disease and inflammatory conditions. The study revealed that stem cells harvested from healthy donor showed more...

  • Hard cell. Skotnicki, Tom // Management Today (14405636);Nov/Dec2013, p12 

    The article focuses on biotechnology entrepreneur Silviu Itescu who founded the stem cell research company Mesoblast. Topics include starting Phase 3 trials into the use of stem cells in the treatment of rheumatoid arthritis, cancer and chronic heart conditions; raising initial public offerings...

  • Cardiac stem cell therapies inch toward clinical litmus test. Sheridan, Cormac // Nature Biotechnology;Jan2013, Vol. 31 Issue 1, p5 

    The article offers information about stem cell therapies for cardiac diseases. It informs that Cardio3 BioSciences SA and Mesoblast Ltd. have started phase 3 trials of bone marrow in congestive heart failure which is derived from mesenchymal cell therapies. A table is presented containing...

  • Life experiences help home in on what truly matters. Skotnicki, Tom // Management Today (14405636);Nov/Dec2013, p15 

    The article focuses on Silviu Itescu, chief executive officer (CEO) of the stem cell research firm Mesoblast, who talks about the impact of terrorist attack in the U.S. on September 9, 2001. He talks about phase 3 trial of stem cell therapy for heart diseases. It mentions that his emphasis on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics